217 results were returned
The Patents Court has refused to grant an Arrow declaration following de-designation of UK from pending patent applications because there was no uncertainty about UK patent rights and the true purpose of the declaration ...
Los medios de comunicación de toda Europa amanecían el pasado 14 de noviembre con la noticia sobre el visto bueno del Gobierno británico al principio de acuerdo alcanzado entre Reino Unido y la Comisión Europea, aunque, ...
A practical cross-border insight into digital health law
On 29 September 2020, the Finnish Competition and Consumer Authority ("FCCA") proposed the Market Court to prohibit the merger between two national healthcare market players, Mehiläinen and Pihlajalinna. If not ...
Globally, many companies are (again) affected by significant decline in business and/or closures as a result of measures taken by governments to deal with the coronavirus. Many of these companies have some form of ...
If a patentee undertakes actions with respect to a patent of the same patent family (e.g. waiving the parent patent of a divisional patent), this is often negatively characterised as playing the “Divisional Game”. We ...
Almost two years ago, the Higher Regional Court Düsseldorf first iterated new liability criteria with respect to Second Medical Use Patents (cf. decision Östrogenblocker of May 5, 2017, docket no. I-2 W 6/17).
Bird & Bird advised AddLife in its acquisition of all shares in the Danish companies Lab-Vent Controls A/S and Koldt & Ryø El A/S.
In February 2019, the President of the UAE, Khalifa bin Zayed Al Nahyan, issued Federal Law No. 2 of 2019 ('the
The French so-called “anti-gift” provisions strictly frame the conditions under which companies in the health sector are allowed to provide advantages, in cash or in kind, to healthcare professionals ("HCPs”)